
==== Front
BMC Cancer
BMC Cancer
BMC Cancer
1471-2407
BioMed Central London

12867
10.1186/s12885-024-12867-6
Research
PAM50 breast cancer subtypes and survival of patients in rural Ethiopia without adjuvant treatment: a prospective observational study
Ballé Judith Katharina 1
Vetter Martina 2
Kenea Tariku Wakuma 3
Eber-Schulz Pia 1
Reibold Christian 1
Ziegenhorn Hannes-Viktor 14
Stückrath Kathrin 2
Wickenhauser Claudia 5
Addissie Adamu 16
Santos Pablo 1
Kantelhardt Eva Johanna 12
Getachew Sefonias 16
Bauer Marcus marcus.bauer@uk-halle.de

15
1 https://ror.org/05gqaka33 grid.9018.0 0000 0001 0679 2801 Global Health Working Group, Institute of Medical Epidemiology, Biostatistics and Informatics, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
2 https://ror.org/05gqaka33 grid.9018.0 0000 0001 0679 2801 Department of Gynaecology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
3 Department of Surgery, Aira General Hospital, Aira, Ethiopia
4 grid.412282.f 0000 0001 1091 2917 Department of Anesthesiology and Critical Care Medicine, Carl Gustav Carus University Hospital, Dresden, Germany
5 https://ror.org/05gqaka33 grid.9018.0 0000 0001 0679 2801 Institute of Pathology, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
6 https://ror.org/038b8e254 grid.7123.7 0000 0001 1250 5688 Department of Epidemiology and Biostatistics, School of Public Health, College of Health Sciences, Addis Ababa University, Addis Ababa, Ethiopia
10 9 2024
10 9 2024
2024
24 112716 5 2024
27 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Purpose

Survival rates of breast cancer (BC) patients are particularly low in rural regions in sub-Saharan Africa (SSA) which is due to limited access to therapy. In recent years, gene expression profiling (GEP) of BC showed a strong prognostic value in patients with local tumour surgery and (neo)adjuvant treatment. The aim of this study was to evaluate the impact of intrinsic subtypes on survival of patients in rural Ethiopia without any (neo)adjuvant therapy.

Methods

In total, 113 female patients from Aira Hospital with histologically proven BC and treated only with surgery were included in this study. All samples were analysed by immunohistochemistry (IHC) for estrogen receptor, progesterone receptor, HER2 and Ki67, as well as RNA-expression analysis for PAM50 subtyping.

Results

A positive hormone receptor status was found in 69.0% of the tumours and intrinsic subtyping demonstrated Luminal B to be the most common subtype (34.5%). Follow-up data was available for 79 of 113 patients. Two-year overall survival (OS) was 57.3% and a considerably worse OS was observed in patients with Basal-like BC compared to Luminal A BC. Moreover, advanced tumours showed an increased risk of mortality.

Conclusion

The OS was very low in the patient cohort that received no (neo)adjuvant treatment. Immunohistochemistry and GEP confirmed endocrine-sensitive tumours in more than half of the patients, with a large proportion of Luminal B, HER2-enriched and Basal-like tumours so that adjuvant chemotherapy should be recommended.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12885-024-12867-6.

Keywords

Africa
Ethiopia
Breast Cancer
PAM50
Intrinsic subtypes
Survival
Martin-Luther-Universität Halle-Wittenberg (1043)Open Access funding enabled and organized by Projekt DEAL.

issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

Breast cancer (BC) is the most common malignancy among women in sub-Saharan Africa (SSA) and the second leading cause of cancer-related deaths [1]. In comparison to high income countries, survival of BC patients is much lower for most countries in SSA [2, 3]. Previous studies from Ethiopia showed two-year survival numbers between 53% and 74% and a 5-year survival of 46% [4]. In contrast, countries with more developed health care systems observe survival rates of around 90% after 5 years [5]. Various factors contribute to these disparities, amongst them late stages of presentation as well as limited diagnostic and treatment capabilities [6, 7].

Gene expression profiling (GEP) has had a major impact on gaining a better understanding of the heterogeneity of breast cancer. GEP may help to identify distinct molecular signatures that demonstrated prognostic impact for BC patients [8]. Later, Parker and colleagues simplified the profiling algorithms using 50 genes for classification of the intrinsic subtypes [9]. Nowadays, four subtypes, namely Luminal A, Luminal B, Human Epidermal Growth Factor 2 (HER2)-enriched and Basal-like subtype can be distinguished, which have been studied in systemically treated patients [8]. By employing GEP, significant disparities in the proportion of the subtypes in different populations have been reported in recent years. This was associated with varied risk factors and therapy sensitivity as well as risk of recurrence and mortality [10]. Insights gained through GEP can add valuable information about prognosis and presumable response to therapy. For instance, patients with Luminal A subtype show a high sensitivity for endocrine treatment, meanwhile response to hormone therapy only is much lower among patients with Luminal B subtype, who additionally need chemotherapy to improve their prognosis [11].

However, GEP based BC subtyping is expensive and has so far not been implemented in most low- and middle-income countries (LMICs). As a surrogate, histopathology and immunohistochemistry (IHC) for estrogen receptor (ER), progesterone receptor (PgR), HER2, and Ki67 proliferation index is commonly used to describe the different BC groups and provides prognostic information to facilitate treatment decision making. Numerous studies have investigated the prevalence of IHC-based BC groups in SSA, pointing out regional differences of hormone receptor expression of BC [12]. Nevertheless, it could be demonstrated that grouping based on IHC is inferior in providing prognostic information compared to gene expression subtyping, which could lead to wrong treatment decisions and poorer survival rates [13–17]. However, IHC is not readily available in SSA [7]. In Ethiopia, the availability of IHC is limited to a few central hospitals and this limitation is more severe in rural areas [18]. Therefore, data is needed to gain a better insight into the tumour biology and consequently to improve breast cancer survival through a more personalised therapy in SSA.

The aim of this study was to analyse whether IHC grouping and intrinsic subtyping predicts patients’ survival in a cohort of BC patients without (neo)adjuvant treatment. Our prior work found a large proportion of tumours to be hormone-receptor positive [19]. We therefore assumed that GEP determines numerous Luminal subtypes. For that reason, we utilised PAM50 gene expression assay for intrinsic breast cancer subtyping and evaluated the prevalence of intrinsic subtypes in comparison to IHC grouping and further histopathological factors like grading and their impact on overall survival (OS) in a cohort of BC patients without any (neo)adjuvant therapy.

Methods

Study design, patients, and tumour characteristics

Female BC patients were included in this study in accordance with the REMARK criteria [20]. Tissue specimens were prospectively collected from 144 patients at the Aira General Hospital, Ethiopia, between 2010 and 2018. Aira Hospital is a primary level hospital located approximately 500 km west of the capital Addis Ababa in the rural Oromyia region. The facility serves approximately 500,000 people and performs approximately 90 breast surgeries annually. The only available treatment option during the time was surgery. Adjuvant chemotherapy and radiation were not available in Aira. All patients had clinically suspicious breast tumour lesions and underwent surgery without prior core needle biopsy. Of these 144 patients, 31 were excluded due to benign BC tumour lesions (n = 4), insufficient tumour tissue or non-invasive precursor lesions (n = 27). For the cross-sectional analysis, 113 BC patients were identified (Fig. 1). Patients’ demographic and clinicopathologic data was collected from medical records. Clinical and histopathological data are summarized in Table 1. Follow-up data were available for 79 patients, with a median follow-up time of 22 months (range 1 day – 72.3 months).

Fig. 1 Enrolment of the study cohort

Histopathology and immunohistochemistry (IHC)

Formalin-fixed and paraffin embedded (FFPE) specimens were centrally analysed at the Institute of Pathology, University Hospital Halle, Martin Luther University Halle-Wittenberg, Germany. All samples were analysed by histomorphology using haematoxylin and eosin (H&E) staining for histological diagnosis according to the World Health Organization (WHO) classification of breast tumours, 5th Edition, 2019. Grading was determined according to Nottingham grading system by Elston and Ellis [21]. All samples were analysed by conventional IHC using antibodies directed against the estrogen receptor (ER), progesterone receptor (PgR), HER2 and Ki67 (Supplementary Table S1). IHC staining was performed on a Bond III automated immunostainer (Leica Biosystems Nussloch GmbH, Wetzlar, Germany) using the Bond Polymer Refine Detection Kit (DS9800-CN). Expression analysis of ER and PgR status was performed according to the current guidelines [22]. A negative ER or PgR status was declared as receptor expression of < 1% of tumour cells. If at least one of the markers was positive, the hormone receptor status was defined as positive. HER2 status was assessed according to the American Society of Clinical Oncology and College of American Pathologists (ASC-CAP) guidelines [23]. The Ki67 proliferation index was visually classified as high if more than 25% of the tumour cells stained positive [24]. BC subtypes were classified according to the surrogate IHC group classification using hormone receptor expression of ER and PgR, the HER2 status as well as Ki67 proliferation index including the following IHC groups: Luminal A-like, Luminal B-like, HER2 positive, and triple negative BC (TNBC) [25].

RNA isolation and expression analysis

Prior to RNA isolation, FFPE specimens were microdissected. For RNA isolation, two to four 10-µm thick tissue slides were used. Deparaffinisation of FFPE tissues was performed 2 times with xylene for 5 min, followed by incubation in 96% and 70% ethanol for 2 min each. Proteinase K digestion was performed for up to 2 h at 56 °C followed by 15 min at 80 °C. RNA was isolated with miRNeasy Mini FFPE Kit® (Qiagen, Venlo, The Netherlands) according to the manufacturer’s instructions. RNA expression analysis was performed using the NanoString Assay according to the hybridisation protocol for the nCounter® XT CodeSet Gene Expression Assay (NanoString nCounter®, Seattle, WA, USA). Following analysis of data was performed according to the nCounter Expression Data Analysis Guide (MAN- C0011-04 from 2017). The expression levels were appraised using the R package NanoStringNorm (github.com/sgrote/NanoStringNormalizeR/). The PAM50 gene algorithm was used to determine the intrinsic breast cancer subtypes [9].

Endpoints and statistical analysis

The study’s first objective was to evaluate the distribution of intrinsic subtypes in BC in a cohort of rural Ethiopian patients. The second objective was to evaluate the impact of intrinsic subtypes to clinical outcome with regard to OS of patients without any (neo)adjuvant treatment. OS included deaths from breast cancer, non-breast cancer, and unknown causes [26]. If survival status was not clear, patients were censored at the last timepoint of contact. OS analysis was performed using the Kaplan-Meier estimator method and the log-rank test. The prognostic value was determined by univariate and multivariate Cox’s proportional hazards models. Clinically relevant prognostic factors included in the model were age, Nottingham grade, tumour size, lymph node status and PAM50 subtypes. The hazard ratios (HR) were presented with 95% confidence intervals (CI), p values below 0.05 were considered statistically significant. Statistical analyses were performed using SPSS 28 (IBM, Armonk NY, USA).

Results

General epidemiological and clinical characteristics

A total of 113 patients from rural Ethiopian regions were included in this study. The median age of patients at time of diagnosis was 42 years (ranging between 16 and 80). Around 75% of patients reported being illiterate and four out of five women lived in rural areas outside the town of Aira. The mean walking time to reach the local hospital was 6.5 h. Only 11.5% of women lived in the urbanised Aira region, 55.7% lived in a rural area and of 11.5% of patients the site of residence was unknown. The mean number of births per woman was 4.8 and 90% of them reported breastfeeding (with a mean total duration of 11.5 years or 2.4 years breastfeeding per child). Nearly half of patients reported having had symptoms for more than 12 months before first consulting a doctor.

Clinical information was available of 76 patients (67.2%), and most patients (n = 44; 57.9%) presented clinically at advanced stage with tumour size larger than 5 cm in diameter. Clinical lymph node involvement was observed in 80.5% of cases. Distant metastases were clinically reported for six patients. No diagnostic imaging or pathological analysis were available locally. No radiotherapy and no chemotherapy were reported. Detailed information is given in Table 1.

Table 1 Epidemiological and clinical characteristics of the cohort

Characteristics (n with information available)	n (% or range)	
age at diagnosis	42 years (range: 16–80)	
 <35	30 (26.5%)	
 35–50	61 (53.9%)	
 > 50	17 (15.1%)	
 missing data	17 (15.1%)	
time of diagnosis		
 2009–2011	38 (33.6%)	
 2012–2014	40 (35.4%)	
 2015–2018	35 (31.0%)	
site of residence		
 rural	63 (55.7%)	
 town	13 (11.5%)	
 missing data	37 (32.8%)	
number of births (n = 64)	4.8 (range: 0–12)	
number of children (n = 79)	4.1 (range: 0–11)	
time to presentation		
 ≤ 12 months	38 (33.6%)	
 > 12 months	31 (27.4%)	
 missing data	44 (39.0%)	
clinical tumour size		
 cT1 (< 2 cm)	4 (3.5%)	
 cT2 (≥ 2 cm, < 5 cm)	29 (25.7%)	
 cT3 (≥ 5 cm)	29 (25.7%)	
 cT4	15 (13.3%)	
 missing data	36 (31.8%)	
clinical lymph node status		
 cN negative	22 (19.5%)	
 cN positive	91 (80.5%)	
distant metastases		
 cM negative	73 (64.6%)	
 cM positive	6 (5.3%)	
 missing data	34 (30.1%)	
surgical treatment		
 simple mastectomy	9 (8.0%)	
 modified radical mastectomy	22 (19.5%)	
 radical mastectomy	3 (2.7%)	
 lumpectomy	8 (7.1%)	
 quadrantectomy	8 (7.1%)	
 mastectomy (not specified)	18 (15.9%)	
 missing data	45 (39.8%)	
stage*		
 localized	20 (17.7%)	
 local spread	1 (0.9%)	
 regional spread	49 (43.4%)	
 advanced	6 (5.3%)	
 missing data	37 (32.7%)	
observation time (n = 79)		
 median OS	22 months

(1 day – 72.3 months)

	
 mean OS	34 months

(SD 18.1 months)

	
*According to European Network of Cancer Registries (ENCR) recommendations (condensed TNM for coding the extent of disease)

Immunohistochemical analysis and molecular subtyping revealed a high prevalence of hormone receptor positive and Luminal breast cancer

Histological assessment revealed a predominance of invasive BC of no special type (NST) which was identified in 109 patients (96.5%). The vast majority of patients showed a Nottingham grade 3 (72.6%). An invasion of lymphatic or blood vessels was observed in 66.4% and 8.9% of cases, respectively. IHC analysis for 113 BC specimens demonstrated that 58.4% and 54.9% of the tumours were ER and PgR positive, respectively. The prevalence of HER2 positive tumours was 24.8% and for TNBC was 20.4%. A high proliferation index of Ki67 staining (cut off > 25%) was observed in 61.9%. Next, molecular subtyping using the PAM50 gene expression algorithm revealed Luminal B subtype to be the most common subtype in this cohort with a frequency of 34.5%. HER2-enriched tumours were determined in 23.0% of samples. The prevalence of Basal-like and Luminal A subtype was 22.1% and 20.4%, respectively (Table 2). Comparison of IHC groups and intrinsic subtypes is shown in Fig. 2. This analysis highlights a low concordance between Luminal B-like and Luminal B classification. This low agreement is also highlighted by a Cohen’s kappa of 0.167 (p < 0.001).

Fig. 2 Comparison of IHC groups and intrinsic subtypes. Color-coded cross table of 113 BC tissue samples grouped according to IHC groups (columns) and intrinsic subtypes (rows). The cell colour gradient indicates the relationship in terms of the numbers of samples that fit in both classifications (IHC groups and intrinsic subtyping)

Table 2 Histological, immunohistochemical characteristics and intrinsic subtype distribution if the cohort

Characteristics	n (%)	
histological type		
 NST	109 (96.5%)	
 other	4 (3.5%)*	
Nottingham grade		
 grade 1	2 (1.8%)	
 grade 2	29 (25.6%)	
 grade 3	82 (72.6%)	
lymphatic vessel invasion		
 no	38 (33.6%)	
 yes	75 (66.4%)	
blood vessel invasion		
 no	103 (91.1%)	
 yes	10 (8.9%)	
hormone receptor status		
 negative	35 (31.0%)	
 positive	78 (69.0%)	
ER status		
 negative	47 (41.6%)	
 positive	66 (58.4%)	
PgR status		
 negative	51 (45.1%)	
 positive	62 (54.9%)	
HER2 status		
 negative	85 (75.2%)	
 positive	28 (24.8%)	
Ki67 proliferation index		
 ≤25%	43 (38.1%)	
 >25%	70 (61.9%)	
IHC groups		
 Luminal A-like	62 (54.9%)	
 Luminal B-like	16 (14.2%)	
 HER2 positive+	12 (10.6%)	
 TNBC	23 (20.3%)	
PAM50 subtypes		
 Luminal A	23 (20.4%)	
 Luminal B	39 (34.5%)	
 HER2-enriched	26 (23.0%)	
 Basal-like	25 (22.1%)	
NST, no special type of carcinoma; ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor 2; * other histological diagnosis included invasive lobular carcinoma and mucinous carcinoma

No differential distributions were detected for age, site of residence, tumour size and stage in the four intrinsic subtypes (see Table 3). However, Basal-like tumours showed higher histopathological grading, more often negative hormone receptor status, and a higher Ki67 proliferation index compared to non-Basal-like tumours. Furthermore, a lower frequency of positive HER2 status was found in these tumours when compared with HER2-enriched subtype.

Table 3 Epidemiological, clinical, and pathological characteristics, stratified by intrinsic subtypes

Characteristics (n)	Luminal A
n (%)	Luminal B
n (%)	HER2-enriched
n (%)	Basal-like
n (%)	p-value
(Fisher’s exact test)	
age (years)					0.906	
 < 35 (30)	6 (27.3%)	13 (33.3%)	7 (28.0%)	4 (18.2%)		
 35–50 (61)	13 (59.1%)	21 (53.8%)	13 (52.0%)	14 (63.6%)		
 > 50 (17)	3 (13.6%)	5 (12.8%)	5 (20.0%)	4 (18.2%)		
site of residence					0.187	
 rural (63)	9 (69.2%)	26 (89.7%)	14 (73.7%)	14 (93.3%)		
 urban (13)	4 (30.8%)	3 (10.3%)	5 (26.3%)	1 (6.7%)		
clinical tumour size					0.103	
 cT1, < 2 cm (4)	1 (7.1%)	3 (10.3%)	0	0		
 cT2, ≥ 2 cm, < 5 cm (29)	8 (57.1%)	7 (24.1%)	9 (47.7%)	5 (33.3%)		
 cT3, ≥ 5 cm (29)	4 (28.6%)	12 (41.4%)	9 (47.7%)	4 (26.7%)		
 cT4 (15)	1 (7.1%)	7 (24.1%)	1 (5.3%)	6 (40.0%)		
lymph node status					0.454	
 cN negative (22)	6 (42.9%)	6 (20.7%)	5 (26.3%)	5 (33.3%)		
 cN positive (55)	8 (57.1%)	23 (79.3%)	14 (73.7%)	10 (66.7%)		
distant metastases					0.785	
 cM negative (73)	14 (100.0%)	28 (90.3%)	17 (89.5%)	14 (93.3%)		
 cM positive (6)	0	3 (9.7%)	2 (10.5%)	1 (6.7%)		
stage*					0.618	
 localized (20)	6 (42.9%)	4 (14.3%)	5 (26.3%)	5 (33.3%)		
 local Spread (1)	0	1 (3.6%)	0	0		
 regional Spread (49)	8 (57.1%)	20 (71.4%)	12 (63.2%)	9 (60.0%)		
 advanced (6)	0	3 (10.7%)	2 (10.5%)	1 (6.7%)		
Nottingham grade					< 0.001	
 grade 1 (2)	2 (8.7%)	0	0	0		
 grade 2 (29)	14 (60.9%)	9 (23.1%)	4 (15.4%)	2 (8.0%)		
 grade 3 (82)	7 (30.4%)	30 (76.9%)	22 (84.6%)	23 (92.0%)		
hormone receptor status					< 0.001	
 negative (35)	1 (4.3%)	1 (2.6%)	16 (61.5%)	17 (68.0%)		
 positive (78)	22 (95.7%)	38 (97.4%)	10 (38.5%)	8 (32.0%)		
HER2 Status					< 0.001	
 negative (85)	20 (87.0%)	34 (87.2%)	7 (26.9%)	24 (96.0%)		
 positive (28)	3 (13.0%)	5 (12.8%)	19 (73.1%)	1 (4.0%)		
Ki67 proliferation index					< 0.001	
 ≤25% (43)	19 (82.6%)	11 (28.2%)	6 (23.1%)	7 (28.0%)		
 >25% (70)	4 (17.4%)	28 (71.8%)	20 (76.9%)	18 (72.0%)		
vital status					0.844	
 dead (42)	6 (42.9%)	17 (54.8%)	10 (52.6%)	9 (60.0%)		
 alive (37)	8 (57.1%)	14 (45.2%)	9 (47.4%)	6 (40.0%)		
ER, estrogen receptor; PgR, progesterone receptor; HER2, human epidermal growth factor receptor. *According to ENCR recommendations (condensed TNM for coding the extent of disease)

Survival analysis showed only minor differences with inferior survival in Basal-like subtype

Follow-up data were available for 79 of 113 patients. The mean OS time was 34 months, and the median OS time was 22 months (ranging from 0 to 72). After two years, 57.3% were still alive (95% confidence interval 45.3-69.3%). The subtype-specific mean OS of the patients with Luminal A, Luminal B, HER2-enriched and Basal-like tumours was 43.6, 36.7, 32.2 and 18.4 months, respectively. We did not observe an effect of intrinsic subtypes on OS in this patient cohort (p = 0.101, Fig. 3).

Fig. 3 Overall survival analysis for 79 patients with regard to intrinsic subtypes

Patients with Basal-like tumours showed the highest probability to pass away within two years of follow-up at 31.6% (95% CI 26,31–36,89) compared to Luminal A tumours (66.7%, 95% CI 56,51–76,89), that also corresponded to a 3.23 higher risk to die (HR 3.23, 95% CI 1.11–9.42). After adjustment to age, Nottingham grade, clinical tumour size, clinical lymph node involvement and non-Basal-like intrinsic subtypes, a higher risk to die was still detectable (HR 7.53, 95%CI 1.78–31.84). In addition, cT3/cT4 tumours were associated with an increased risk of mortality, compared to patients with cT1/cT2 tumours (HR 1.93, 95% CI 1.04–3.59). We did not observe any additional significant associations of intrinsic subtypes with OS, neither in univariate, nor in multivariate analyses (Table 4).

Table 4 Prognostic relevance of intrinsic subtypes in association with clinical and pathological characteristics

Factor	n (%)	Events	Univariate Analysis	Multivariate Analysis	
HR (95% CI)	p-value	HR (95% CI)	p-value	
age (years)							
 ≥ 35 (Ref)	60 (76.0%)	31					
 < 35	19 (24.0%)	11	1.25 (0.62–2.51)	0.540	1.26 (0.61–2.60)	0.535	
Nottingham grade							
 1 or 2 (Ref)	21 (26.6%)	10					
 3	58 (73.4%)	32	1.07 (0.52–2.18)	0.860	0.38 (0.13–1.05)	0.062	
tumour size							
 cT1 or cT2 (Ref)	35 (44.3%)	17					
 cT3 or cT4	44 (55.7%)	25	1.93 (1.04–3.59)	0.037	1.73 (0.89–3.38)	0.109	
lymph node status							
 cN negative (Ref)	22 (27.8%)	8					
 cN positive	57 (72.2%)	34	2.00 (0.92–4.34)	0.079	2.28 (0.99–5.29)	0.054	
intrinsic subtype							
 Luminal A (Ref)	14 (17.7%)	6					
 Luminal B	31 (39.2%)	17	1.33 (0.52–3.38)	0.556	2.28 (0.67–7.76)	0.189	
 HER2-enriched	19 (24.1%)	10	1.68 (0.60–4.67)	0.322	3.35 (0.88–12.79)	0.077	
 Basal-like	15 (19.0%)	9	3.23 (1.11–9.42)	0.032	7.53 (1.78–31.84)	0.006	
Bold characters denote significant HR (p < 0.05). The sample size for the analysis was n = 79. Total number of events is n = 42. HR, Hazard Ratio; CI, confidence interval; Ref, category taken as a reference

Discussion

Cancer is a growing public health concern in SSA [1, 27] and the survival rates of BC are particularly low in this region [28, 29]. In recent years, GEP increasingly used in the clinical management of BC patients to gain a deeper comprehension of this heterogeneous disease. Along with histopathology and IHC for ER, PgR, Ki67 and HER2 status, GEP offer valuable information on prognosis and response to possible (neo)adjuvant treatment [9, 25, 30, 31]. However, due to high costs, GEP is often not feasible in most LMICs. However, in Brazil it has been shown that GEP using Oncotype® DX could be used cost-effective for patients care [32]. To our knowledge, this is the first study that used GEP for intrinsic subtyping to evaluate its impact on OS in BC patients from rural Ethiopia without any relevant systemic treatment.

Of 113 BC patients treated only with surgery in rural Ethiopia, we described tumour biology using PAM50 gene expression assay and compared the intrinsic subtypes with clinical, histological and immunohistochemical characteristics. IHC grouping demonstrated a high prevalence of hormone receptor positive tumours of 69.0% in this BC patient cohort. Previous studies by Eng et al. [12] as well as Hercules et al. [33] found a heterogeneity of the proportions of hormone receptor positive and negative BC in different regions in SSA. Prior work from Ethiopia reported 69.0% [34] and 66.0% [35] Luminal-like subtypes, which is in line with our results. Moreover, in the US a study of BC patients found 10.3% TNBC in patients with European ancestry compared to 22.5% TNBC in non-Hispanic black patients [36], that is comparable with the proportion of TNBC (20.4%) in our cohort. Furthermore, this closely resembles findings from another Ethiopian study, which identified 23.0% [35] of tumours as TNBC. However, the proportions of TNBC found in our study slightly differ from a BC patient cohort from Mozambique (25.0% TNBC) [37] and are considerably lower than described by Ikeri et al. in a Western African cohort (42.1% TNBC) [38]. In a previous study from our group, we found a regional diversity of the distribution of IHC groups with 17.4% in Southern Africa, 22.7% in Eastern Africa and 39.4% in Western Africa [39]. Next to differences in the distribution of IHC groups in SSA population, also genetic differences have been reported [40].

In line with the IHC groups, intrinsic subtyping revealed differences in the proportions of the four subtypes compared to studies of BC patients from the US, which commonly report high numbers of Luminal A of almost half of the samples and a low amount of Basal-like subtype [13, 41]. In another study from the US among 1,319 BC specimens, Luminal A was also the most frequently identified subtype among African Americans (43.4%) [42]. This contrasts with our results, where Luminal B was the most common subtype (34.5%) and only 20.4% of Luminal A tumours could be observed. A larger cohort from Ethiopia also reported a lower proportion of Luminal A subtype compared to Western studies. [43]. In accordance with our results, a recently published South African study by Phakati et al. identified Luminal B as the most common subtype among the 377 BC patients included. Furthermore they found human immunodeficiency virus (HIV)-negativity to be associated with Luminal B subtype [44]. As the HIV status among patients in our cohort is unknown, no statement can be made on a possible correlation between intrinsic subtype and the HIV status.

Comparison of IHC groups and GEP intrinsic subtyping showed an overall good correlation, however, revealed a weakness of IHC grouping to distinguish between Luminal A-like and Luminal B-like tumours. This is also highlighted by a low Cohen’s kappa of 0.167, which is generally classified as a weak agreement. According to IHC grouping, 69.0% of tumours showed a positive hormone receptor expression and can therefore be classified as Luminal-like subtypes, and GEP identified an intrinsic Luminal subtype (Luminal A and B) in 54.9% of BC specimens, like it has been demonstrated before [19, 43]. Using GEP intrinsic subtyping half of the samples of the Luminal A-like IHC group could be allocated to Luminal B intrinsic subtype that showed a higher risk of recurrence. One reason might be due to preanalytical issues that influences the IHC results. This debility of the IHC group classification was already reported by Goldhirsch et al. [45], who suggested to employ IHC grouping as a surrogate subtype classification, while noting that GEP should be preferred to base chemotherapy decisions for patients with Luminal disease. Therefore, downstream survival analysis of our BC patient cohort was performed based only on the GEP intrinsic subtype classification. Two-year OS probability was overall 57.3% (95% CI 4.3%-69.3%) with inferior survival in women with Basal-like subtype. Patient characteristics in our cohort varied widely from those in high income countries, where mainly presentation at early stages and high survival rates are observed [46, 47]. Four in five Ethiopian women were ≤ 50 years old, more than half presented with advanced tumour size and three quarters with poorly differentiated tumours. In addition, surgery was the only treatment received by all patients of our cohort, with modified radical mastectomy (MRM) being the most common operation type. Considering mainly late presentation and lack of radiotherapy services, other surgical procedures often become infeasible [46, 47]. Kantelhardt et al. likewise identified MRM as the surgical procedure of choice in their Ethiopian cohort [4]. Tamoxifen was donated to patients with hormone receptor- positive disease from 2013 on, but due to financial hardship and poor healthcare infrastructure, only one patient adhered to endocrine therapy for more than two years [48]. Subsequently, we consider our cohort as one without any relevant (neo)adjuvant treatment received. McCormack et al. displayed that surgery as the only treatment is associated with inferior survival compared to surgery in addition to adjuvant treatment [29]. As both GEP and IHC confirm high numbers of endocrine- sensitive tumours among women of our East African cohort, access to Tamoxifen and proper long-term implementation of endocrine treatment is essential to improve survival rates. We suggest as demonstrated by Getachew et al. the deployment of trained Breast Nurses to enhance adherence to adjuvant endocrine treatment [49]. Furthermore, as PAM50 subtype distribution showed a large proportion of Luminal B, HER2-enriched and Basal-like tumours additional implementation of chemotherapy would be of advantage to many BC patients in the district of Aira.

Due to late presentation of patients at advanced tumour stages and lack of neoadjuvant or adjuvant therapy regimes this very poor clinical outcome was found. Similar crude two-year survival rates of approximately 60% in stage III BC patients were reported in the African Breast Cancer – Disparities In Outcome (ABC-DO) study [29] Patients of our cohort presenting with cT3/cT4 tumours showed inferior survival compared to more favourable cT1/cT2 tumours. Our results confirm the widely recognized association between large tumour size and poor prognosis [50]. However, in our cohort, patients with Basal-like tumours had worse outcome compared to all other subtypes (31.6% vs. 62.9% survial probability after 24 months) and demonstrated to be a stronger prognostic factor when compared with tumour size. Risk of dying at two years was lowest for Luminal A tumours, with a mean subtype-specific survival time of 43.6 months vs. 18.4 months in patients with Basal-like subtype. These findings are in line with other studies in the US [10, 51], even though OS rates are considerably higher than in our cohort. Phakathi et al. likewise reported differences in GEP subtype-specific survival among HIV-negative patients in their South African cohort [44]. Patients with luminal BC subtypes showed superior survival compared to non-luminal BC subtypes [44]. When we used log-rank test to investigate an effect of intrinsic subtype on survival probability, we did not find any evidence when testing for all four subtypes. One reason for that could be the lack of (neo)adjuvant treatment in our cohort. In comparison, the HIV-negative patients investigated by Phakati and colleagues received systemic treatment with chemotherapy and endocrine treatment but no anti-HER2 therapy [44, 52, 53]. This presumably resulted in superior survival of not only Luminal A but also Luminal B (HR 2.39) BC subtype compared to lower OS probability of patients with HER2-enriched (HR 6.09) and Basal-like subtype (HR 5.47) [44, 53]. However, paucity of data regarding GEP subtype-specific survival in SSA and differences in treatment make the comparison arduous.

Strengths and limitations

To our knowledge, this is the first study that investigated the impact of PAM50 intrinsic BC subtypes on survival of a patient cohort without any (neo)adjuvant treatment of women with BC living in a rural East African area. Through active follow-up including home visits and phone calls, precise information on the patients’ survival status was available. However, follow-up could not be obtained from some patients because they could not be contacted by telephone, or no relatives could be found who could provide relevant data. An additional limitation of this study is the small sample size with possible selection bias as this was not a population-based but a single-center hospital-based cohort. However, the proportions of intrinsic subtypes are comparable with other studies reported in the region. Furthermore, due to the low number of previous research data available, contextualisation and interpretation of our findings is still difficult. Further research using GEP for BC intrinsic subtype classification is needed to gain a deeper understanding of geographic and inter-ethnic differences in tumour biology and survival of BC patients in East Africa.

Conclusion

In our rural patient cohort, nearly half of the female BC patients treated only with surgery died within two years after receiving their diagnosis. An unfavourable prognosis was observed for patients that presented with large tumour size (> 5 cm) and for those that were classified as Basal-like intrinsic subtype compared to patients with non-Basal-like intrinsic subtypes. Both, IHC grouping and intrinsic subtypes showed a large share of endocrine responsive tumours. However, Luminal B intrinsic subtype was the most common intrinsic subtype. This indicates the need to promote both the implementation of endocrine therapy and offer access to chemotherapy in rural Ethiopia in order to improve BC patients’ outcomes. Moreover, a local implementation of BC IHC grouping should be pursued in the routine diagnosis for therapy recommendations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Supplementary Material 2

Abbreviations

ASC-CAP American Society of Clinical Oncology and College of American Pathologists

BC Breast cancer

CI Confidence interval

ER Estrogen receptor

ENCR European network of cancer registries

FFPE Formalin-fixed, paraffin-embedded

GEP Gene expression profiling

HER2 Human Epidermal Growth Factor 2

HIV Human immunodeficiency virus

HR Hazard ratio

IHC Immunohistochemistry

LMIC Low- and middle-income countries

MRM Modified radical mastectomy

NST No special type

OS Overall survival

PAM50 Prediction Analysis of Microarray 50

PgR Progesterone receptor, SSA, sub-Saharan Africa

TNBC Triple negative breast cancer

WHO World Health Organization

Acknowledgements

We want to thank the hospital staff and all patients who provided tumour samples.

Author contributions

JKB contributed to analysis, interpretation and writing of the original and final draft. PES, TWK, AG and CR contributed to study design, sample and data acquisition. MB, KS, EJK, MV contributed to study design, data acquisition, data analysis, data interpretation and editing of the manuscript. JKB, MB, KS and MV carried out the experimental work. JKB, MB, HZ, PS, MV and EJK wrote the manuscript. PS contributed to data analysis, statistics and editing of the manuscript. MB, EJK, CW and AA supervised the team. All authors reviewed and approved the final version of the manuscript.

Funding

Open Access funding enabled and organized by Projekt DEAL. This study was also supported by Else Kroener-Fresenius-Foundation Grant No. 2018_HA31SP. The project on which this publication is based was funded, in part, by the German Federal Ministry of Education and Research 01KA2220B. This research was funded, in part, by Science for Africa Foundation to the Del-22-008 program, with support from the Wellcome Trust and the UK Foreign, Commonwealth & Development Office as part of the EDCPT2 programme supported by the European Union.

Open Access funding enabled and organized by Projekt DEAL.

Data availability

All data generated in this study are available upon request to the corresponding author.

Declarations

Competing interests

The authors declare no competing interests.

Ethics approval

This study was approved by the institutional review boards at Addis Ababa University, Ethiopia (study approval’s reference No. 050/2013 protocol 124/10/IM), and Martin Luther University Halle-Wittenberg, Germany (vote on August 23, 2010 of the “Medizinische Ethikkommission”). Informed consent was obtained from all patients when the pathology specimens were sent to Germany for analysis.

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. International Agency for Research on Cancer, World Health Organization. The Global Cancer Observatory. Population fact sheet: Africa. Source: Globocan 2020. Accessed 21 Aug 2023.
2. Joko-Fru WY Miranda-Filho A Soerjomataram I Breast cancer survival in sub-saharan Africa by age, stage at diagnosis and human development index: a population-based registry study Int J Cancer 2020 146 5 1208 18 10.1002/ijc.32406 31087650
Joko-Fru WY, Miranda-Filho A, Soerjomataram I, et al. Breast cancer survival in sub-saharan Africa by age, stage at diagnosis and human development index: a population-based registry study. Int J Cancer. 2020;146(5):1208–18. 10.1002/ijc.32406.31087650 10.1002/ijc.32406
3. Gakwaya A Kigula-Mugambe JB Kavuma A Cancer of the breast: 5-year survival in a tertiary hospital in Uganda Br J Cancer 2008 99 1 63 7 10.1038/sj.bjc.6604435 18577991
Gakwaya A, Kigula-Mugambe JB, Kavuma A, et al. Cancer of the breast: 5-year survival in a tertiary hospital in Uganda. Br J Cancer. 2008;99(1):63–7. 10.1038/sj.bjc.6604435.18577991 10.1038/sj.bjc.6604435
4. Kantelhardt EJ Zerche P Mathewos A Breast cancer survival in Ethiopia: a cohort study of 1,070 women Int J Cancer 2014 135 3 702 9 10.1002/ijc.28691 24375396
Kantelhardt EJ, Zerche P, Mathewos A, et al. Breast cancer survival in Ethiopia: a cohort study of 1,070 women. Int J Cancer. 2014;135(3):702–9. 10.1002/ijc.28691.24375396 10.1002/ijc.28691
5. Sankaranarayanan R Swaminathan R Brenner H Cancer survival in Africa, Asia, and Central America: a population-based study Lancet Oncol 2010 11 2 165 73 10.1016/S1470-2045(09)70335-3 20005175
Sankaranarayanan R, Swaminathan R, Brenner H, et al. Cancer survival in Africa, Asia, and Central America: a population-based study. Lancet Oncol. 2010;11(2):165–73. 10.1016/S1470-2045(09)70335-3.20005175 10.1016/S1470-2045(09)70335-3
6. Grosse Frie K Samoura H Diop S Why do women with breast Cancer get diagnosed and treated late in Sub-saharan Africa? Perspectives from women and patients in Bamako, Mali. Breast care (Basel Switzerland) 2018 13 1 39 43 10.1159/000481087
Grosse Frie K, Samoura H, Diop S, et al. Why do women with breast Cancer get diagnosed and treated late in Sub-saharan Africa? Perspectives from women and patients in Bamako, Mali. Breast care (Basel. Switzerland). 2018;13(1):39–43. 10.1159/000481087.10.1159/000481087
7. Ziegenhorn H-V Frie KG Ekanem I-O Breast cancer pathology services in sub-saharan Africa: a survey within population-based cancer registries BMC Health Serv Res 2020 20 1 912 10.1186/s12913-020-05752-y 33008380
Ziegenhorn H-V, Frie KG, Ekanem I-O, et al. Breast cancer pathology services in sub-saharan Africa: a survey within population-based cancer registries. BMC Health Serv Res. 2020;20(1):912. 10.1186/s12913-020-05752-y.33008380 10.1186/s12913-020-05752-y
8. Perou CM Sørlie T Eisen MB Molecular portraits of human breast tumours Nature 2000 406 6797 747 52 10.1038/35021093 10963602
Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52. 10.1038/35021093.10963602 10.1038/35021093
9. Parker JS Mullins M Cheang MCU Supervised risk predictor of breast cancer based on intrinsic subtypes J Clin Oncology: Official J Am Soc Clin Oncol 2009 27 8 1160 7 10.1200/JCO.2008.18.1370
Parker JS, Mullins M, Cheang MCU, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncology: Official J Am Soc Clin Oncol. 2009;27(8):1160–7. 10.1200/JCO.2008.18.1370.10.1200/JCO.2008.18.1370
10. Caan BJ Sweeney C Habel LA Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research Cosponsored Am Soc Prev Oncol 2014 23 5 725 34 10.1158/1055-9965.EPI-13-1017
Caan BJ, Sweeney C, Habel LA, et al. Intrinsic subtypes from the PAM50 gene expression assay in a population-based breast cancer survivor cohort: prognostication of short- and long-term outcomes. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research. Cosponsored Am Soc Prev Oncol. 2014;23(5):725–34. 10.1158/1055-9965.EPI-13-1017.10.1158/1055-9965.EPI-13-1017
11. Ades F Zardavas D Bozovic-Spasojevic I Luminal B breast cancer: molecular characterization, clinical management, and future perspectives J Clin Oncology: Official J Am Soc Clin Oncol 2014 32 25 2794 803 10.1200/JCO.2013.54.1870
Ades F, Zardavas D, Bozovic-Spasojevic I, et al. Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncology: Official J Am Soc Clin Oncol. 2014;32(25):2794–803. 10.1200/JCO.2013.54.1870.10.1200/JCO.2013.54.1870
12. Eng A McCormack V Dos-Santos-Silva I Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis PLoS Med 2014 11 9 e1001720 10.1371/journal.pmed.1001720 25202974
Eng A, McCormack V, Dos-Santos-Silva I. Receptor-defined subtypes of breast cancer in indigenous populations in Africa: a systematic review and meta-analysis. PLoS Med. 2014;11(9):e1001720. 10.1371/journal.pmed.1001720.25202974 10.1371/journal.pmed.1001720
13. Bastien RRL Rodríguez-Lescure Á Ebbert MTW PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers BMC Med Genom 2012 5 44 10.1186/1755-8794-5-44
Bastien RRL, Rodríguez-Lescure Á, Ebbert MTW, et al. PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genom. 2012;5:44. 10.1186/1755-8794-5-44.10.1186/1755-8794-5-44
14. Chia SK Bramwell VH Tu D A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen Clin cancer Research: Official J Am Association Cancer Res 2012 18 16 4465 72 10.1158/1078-0432.CCR-12-0286
Chia SK, Bramwell VH, Tu D, et al. A 50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin cancer Research: Official J Am Association Cancer Res. 2012;18(16):4465–72. 10.1158/1078-0432.CCR-12-0286.10.1158/1078-0432.CCR-12-0286
15. Kim HK Park KH Kim Y Discordance of the PAM50 intrinsic subtypes compared with immunohistochemistry-based surrogate in breast Cancer patients: potential implication of genomic alterations of discordance Cancer Res Treat 2019 51 2 737 47 10.4143/crt.2018.342 30189722
Kim HK, Park KH, Kim Y, et al. Discordance of the PAM50 intrinsic subtypes compared with immunohistochemistry-based surrogate in breast Cancer patients: potential implication of genomic alterations of discordance. Cancer Res Treat. 2019;51(2):737–47. 10.4143/crt.2018.342.30189722 10.4143/crt.2018.342
16. Nielsen TO Parker JS Leung S A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer Clin cancer Research: Official J Am Association Cancer Res 2010 16 21 5222 32 10.1158/1078-0432.CCR-10-1282
Nielsen TO, Parker JS, Leung S, et al. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin cancer Research: Official J Am Association Cancer Res. 2010;16(21):5222–32. 10.1158/1078-0432.CCR-10-1282.10.1158/1078-0432.CCR-10-1282
17. Dix-Peek T Phakathi BP van den Berg EJ Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer Breast Cancer Res Treat 2023 199 1 1 12 10.1007/s10549-023-06886-3 36867282
Dix-Peek T, Phakathi BP, van den Berg EJ, et al. Discordance between PAM50 intrinsic subtyping and immunohistochemistry in South African women with breast cancer. Breast Cancer Res Treat. 2023;199(1):1–12. 10.1007/s10549-023-06886-3.36867282 10.1007/s10549-023-06886-3
18. Okubazgi G Berhane B Nigussie M Status of Histopathology services in Ethiopia Am J Clin Pathol 2020 153 1 3 4 10.1093/ajcp/aqz144 31586440
Okubazgi G, Berhane B, Nigussie M, et al. Status of Histopathology services in Ethiopia. Am J Clin Pathol. 2020;153(1):3–4. 10.1093/ajcp/aqz144.31586440 10.1093/ajcp/aqz144
19. Eber-Schulz P Tariku W Reibold C Survival of breast cancer patients in rural Ethiopia Breast Cancer Res Treat 2018 170 1 111 8 10.1007/s10549-018-4724-z 29479644
Eber-Schulz P, Tariku W, Reibold C, et al. Survival of breast cancer patients in rural Ethiopia. Breast Cancer Res Treat. 2018;170(1):111–8. 10.1007/s10549-018-4724-z.29479644 10.1007/s10549-018-4724-z
20. McShane LM Altman DG Sauerbrei W REporting recommendations for tumour MARKer prognostic studies (REMARK) Br J Cancer 2005 93 4 387 91 10.1038/sj.bjc.6602678 16106245
McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Br J Cancer. 2005;93(4):387–91. 10.1038/sj.bjc.6602678.16106245 10.1038/sj.bjc.6602678
21. Lokuhetty D, White VA, Watanabe R, et al. editors. (2019) Breast tumours, 5th ed. World Health Organization Classification of tumours, vol 2. International Agency for Research on Cancer, Lyon.
22. Allison KH Hammond MEH Dowsett M Estrogen and progesterone receptor testing in breast Cancer: ASCO/CAP Guideline Update J Clin Oncology: Official J Am Soc Clin Oncol 2020 38 12 1346 66 10.1200/JCO.19.02309
Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast Cancer: ASCO/CAP Guideline Update. J Clin Oncology: Official J Am Soc Clin Oncol. 2020;38(12):1346–66. 10.1200/JCO.19.02309.10.1200/JCO.19.02309
23. Wolff AC Hammond MEH Allison KH Human epidermal growth factor receptor 2 testing in breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update J Clin Oncology: Official J Am Soc Clin Oncol 2018 36 20 2105 22 10.1200/JCO.2018.77.8738
Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncology: Official J Am Soc Clin Oncol. 2018;36(20):2105–22. 10.1200/JCO.2018.77.8738.10.1200/JCO.2018.77.8738
24. Petrelli F Viale G Cabiddu M Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients Breast Cancer Res Treat 2015 153 3 477 91 10.1007/s10549-015-3559-0 26341751
Petrelli F, Viale G, Cabiddu M, et al. Prognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients. Breast Cancer Res Treat. 2015;153(3):477–91. 10.1007/s10549-015-3559-0.26341751 10.1007/s10549-015-3559-0
25. Goldhirsch A Wood WC Coates AS Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast Cancer 2011 Annals Oncology: Official J Eur Soc Med Oncol 2011 22 8 1736 47 10.1093/annonc/mdr304
Goldhirsch A, Wood WC, Coates AS, et al. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast Cancer 2011. Annals Oncology: Official J Eur Soc Med Oncol. 2011;22(8):1736–47. 10.1093/annonc/mdr304.10.1093/annonc/mdr304
26. Tolaney SM Garrett-Mayer E White J Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast Cancer clinical trials: STEEP Version 2.0 J Clin Oncology: Official J Am Soc Clin Oncol 2021 39 24 2720 31 10.1200/JCO.20.03613
Tolaney SM, Garrett-Mayer E, White J, et al. Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast Cancer clinical trials: STEEP Version 2.0. J Clin Oncology: Official J Am Soc Clin Oncol. 2021;39(24):2720–31. 10.1200/JCO.20.03613.10.1200/JCO.20.03613
27. Hamdi Y Abdeljaoued-Tej I Zatchi AA Cancer in Africa: the Untold Story Front Oncol 2021 11 650117 10.3389/fonc.2021.650117 33937056
Hamdi Y, Abdeljaoued-Tej I, Zatchi AA, et al. Cancer in Africa: the Untold Story. Front Oncol. 2021;11:650117.33937056 10.3389/fonc.2021.650117
28. Weiner CM Mathewos A Addissie A Characteristics and follow-up of metastatic breast cancer in Ethiopia: a cohort study of 573 women Breast (Edinburgh Scotland) 2018 42 23 30 10.1016/j.breast.2018.08.095 30149234
Weiner CM, Mathewos A, Addissie A, et al. Characteristics and follow-up of metastatic breast cancer in Ethiopia: a cohort study of 573 women. Breast (Edinburgh Scotland). 2018;42:23–30. 10.1016/j.breast.2018.08.095.30149234 10.1016/j.breast.2018.08.095
29. McCormack V McKenzie F Foerster M Breast cancer survival and survival gap apportionment in sub-saharan Africa (ABC-DO): a prospective cohort study Lancet Global Health 2020 8 9 e1203 12 10.1016/S2214-109X(20)30261-8 32827482
McCormack V, McKenzie F, Foerster M, et al. Breast cancer survival and survival gap apportionment in sub-saharan Africa (ABC-DO): a prospective cohort study. Lancet Global Health. 2020;8(9):e1203–12. 10.1016/S2214-109X(20)30261-8.32827482 10.1016/S2214-109X(20)30261-8
30. Dai X Li T Bai Z Breast cancer intrinsic subtype classification, clinical use and future trends Am J cancer Res 2015 5 10 2929 43 26693050
Dai X, Li T, Bai Z, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J cancer Res. 2015;5(10):2929–43.26693050
31. Elston CW Ellis IO Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up Histopathology 1991 19 5 403 10 10.1111/j.1365-2559.1991.tb00229.x 1757079
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403–10. 10.1111/j.1365-2559.1991.tb00229.x.1757079 10.1111/j.1365-2559.1991.tb00229.x
32. Oliveira LC Megid TBC Rosa DD Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study JCO 2022 40 16suppl e18822 18822 10.1200/JCO.2022.40.16_suppl.e18822
Oliveira LC, Megid TBC, Rosa DD, et al. Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study. JCO. 2022;40(16suppl):e18822–18822. 10.1200/JCO.2022.40.16_suppl.e18822.10.1200/JCO.2022.40.16_suppl.e18822
33. Hercules SM Alnajar M Chen C Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis BMJ open 2022 12 5 e055735 10.1136/bmjopen-2021-055735 35623750
Hercules SM, Alnajar M, Chen C, et al. Triple-negative breast cancer prevalence in Africa: a systematic review and meta-analysis. BMJ open. 2022;12(5):e055735. 10.1136/bmjopen-2021-055735.35623750 10.1136/bmjopen-2021-055735
34. Kantelhardt EJ Mathewos A Aynalem A The prevalence of estrogen receptor-negative breast cancer in Ethiopia BMC Cancer 2014 14 895 10.1186/1471-2407-14-895 25433805
Kantelhardt EJ, Mathewos A, Aynalem A, et al. The prevalence of estrogen receptor-negative breast cancer in Ethiopia. BMC Cancer. 2014;14:895. 10.1186/1471-2407-14-895.25433805 10.1186/1471-2407-14-895
35. Hadgu E Seifu D Tigneh W Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa BMC Womens Health 2018 18 1 40 10.1186/s12905-018-0531-2 29444670
Hadgu E, Seifu D, Tigneh W, et al. Breast cancer in Ethiopia: evidence for geographic difference in the distribution of molecular subtypes in Africa. BMC Womens Health. 2018;18(1):40. 10.1186/s12905-018-0531-2.29444670 10.1186/s12905-018-0531-2
36. Howlader N, Altekruse SF, Li CI, et al. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014;106(5). 10.1093/jnci/dju055.
37. Brandão M Guisseve A Bata G Breast cancer subtypes: implications for the treatment and survival of patients in Africa-a prospective cohort study from Mozambique ESMO Open 2020 5 5 e000829 10.1136/esmoopen-2020-000829 33020218
Brandão M, Guisseve A, Bata G, et al. Breast cancer subtypes: implications for the treatment and survival of patients in Africa-a prospective cohort study from Mozambique. ESMO Open. 2020;5(5):e000829. 10.1136/esmoopen-2020-000829.33020218 10.1136/esmoopen-2020-000829
38. Ikeri NZ Oguntunde OA Igbokwe U Breast Cancer in a Lagos Facility: implications for the Institution of a Cancer Screening Programme Pathobiol J ImmunoPathol Mol Cell Biol 2018 85 4 254 60 10.1159/000489933
Ikeri NZ, Oguntunde OA, Igbokwe U, et al. Breast Cancer in a Lagos Facility: implications for the Institution of a Cancer Screening Programme. Pathobiol J ImmunoPathol Mol Cell Biol. 2018;85(4):254–60. 10.1159/000489933.10.1159/000489933
39. Bauer M Vetter M Stückrath K Regional Variation in the Tumor Microenvironment, Immune escape and prognostic factors in breast Cancer in Sub-saharan Africa Cancer Immunol Res 2023 11 6 720 31 10.1158/2326-6066.CIR-22-0795 37058582
Bauer M, Vetter M, Stückrath K, et al. Regional Variation in the Tumor Microenvironment, Immune escape and prognostic factors in breast Cancer in Sub-saharan Africa. Cancer Immunol Res. 2023;11(6):720–31. 10.1158/2326-6066.CIR-22-0795.37058582 10.1158/2326-6066.CIR-22-0795
40. Ansari-Pour N Zheng Y Yoshimatsu TF Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes Nat Commun 2021 12 1 6946 10.1038/s41467-021-27079-w 34836952
Ansari-Pour N, Zheng Y, Yoshimatsu TF, et al. Whole-genome analysis of Nigerian patients with breast cancer reveals ethnic-driven somatic evolution and distinct genomic subtypes. Nat Commun. 2021;12(1):6946. 10.1038/s41467-021-27079-w.34836952 10.1038/s41467-021-27079-w
41. Kensler KH Sankar VN Wang J PAM50 molecular intrinsic subtypes in the nurses’ health study cohorts. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research Cosponsored Am Soc Prev Oncol 2019 28 4 798 806 10.1158/1055-9965.EPI-18-0863
Kensler KH, Sankar VN, Wang J, et al. PAM50 molecular intrinsic subtypes in the nurses’ health study cohorts. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research. Cosponsored Am Soc Prev Oncol. 2019;28(4):798–806. 10.1158/1055-9965.EPI-18-0863.10.1158/1055-9965.EPI-18-0863
42. Sweeney C, Bernard PS, Factor RE et al. (2014) Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 23(5):714–724. 10.1158/1055-9965.EPI-13-1023
43. Desalegn Z Yohannes M Porsch M Intrinsic subtypes in Ethiopian breast cancer patient Breast Cancer Res Treat 2022 196 3 495 504 10.1007/s10549-022-06769-z 36282363
Desalegn Z, Yohannes M, Porsch M, et al. Intrinsic subtypes in Ethiopian breast cancer patient. Breast Cancer Res Treat. 2022;196(3):495–504. 10.1007/s10549-022-06769-z.36282363 10.1007/s10549-022-06769-z
44. Phakathi B Dix-Peek T van den Berg E PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients-a South African cohort study Breast Cancer Res Treat 2023 200 3 337 46 10.1007/s10549-023-06969-1 37266756
Phakathi B, Dix-Peek T, van den Berg E, et al. PAM50 intrinsic subtypes, risk of recurrence score and breast cancer survival in HIV-positive and HIV-negative patients-a South African cohort study. Breast Cancer Res Treat. 2023;200(3):337–46. 10.1007/s10549-023-06969-1.37266756 10.1007/s10549-023-06969-1
45. Goldhirsch A Winer EP Coates AS Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast Cancer 2013 Annals Oncology: Official J Eur Soc Med Oncol 2013 24 9 2206 23 10.1093/annonc/mdt303
Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast Cancer 2013. Annals Oncology: Official J Eur Soc Med Oncol. 2013;24(9):2206–23. 10.1093/annonc/mdt303.10.1093/annonc/mdt303
46. Bryan S Masoud H Weir HK Cancer in Canada: stage at diagnosis Health Rep 2018 29 12 21 5 30566206
Bryan S, Masoud H, Weir HK, et al. Cancer in Canada: stage at diagnosis. Health Rep. 2018;29(12):21–5.30566206
47. Johnson HM Irish W Vohra NA Refining breast cancer prognosis by incorporating age at diagnosis into clinical prognostic staging: introduction of a novel online calculator Breast Cancer Res Treat 2021 187 3 805 14 10.1007/s10549-021-06113-x 33609208
Johnson HM, Irish W, Vohra NA, et al. Refining breast cancer prognosis by incorporating age at diagnosis into clinical prognostic staging: introduction of a novel online calculator. Breast Cancer Res Treat. 2021;187(3):805–14. 10.1007/s10549-021-06113-x.33609208 10.1007/s10549-021-06113-x
48. Reibold CF Tariku W Eber-Schulz P Adherence to newly implemented tamoxifen therapy for breast Cancer patients in Rural Western Ethiopia Breast care (Basel Switzerland) 2021 16 5 484 90 10.1159/000512840 34720808
Reibold CF, Tariku W, Eber-Schulz P, et al. Adherence to newly implemented tamoxifen therapy for breast Cancer patients in Rural Western Ethiopia. Breast care (Basel Switzerland). 2021;16(5):484–90. 10.1159/000512840.34720808 10.1159/000512840
49. Getachew S Addissie A Seife E Breast nurse intervention to improve adherence to endocrine therapy among breast Cancer patients in South Ethiopia Oncologist 2022 27 8 e650 60 10.1093/oncolo/oyac081 35524760
Getachew S, Addissie A, Seife E, et al. Breast nurse intervention to improve adherence to endocrine therapy among breast Cancer patients in South Ethiopia. Oncologist. 2022;27(8):e650–60. 10.1093/oncolo/oyac081.35524760 10.1093/oncolo/oyac081
50. Carter CL Allen C Henson DE Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases Cancer 1989 63 1 181 7 10.1002/1097-0142(19890101)63:1<181:AID-CNCR2820630129>3.0.CO;2-H 2910416
Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63(1):181–7. 10.1002/1097-0142(19890101)63:1%3C181:AID-CNCR2820630129%3E3.0.CO;2-H.2910416 10.1002/1097-0142(19890101)63:1<181:AID-CNCR2820630129>3.0.CO;2-H
51. Liu MC Pitcher BN Mardis ER PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance) NPJ Breast Cancer 2016 2 15023 10.1038/npjbcancer.2015.23 28691057
Liu MC, Pitcher BN, Mardis ER, et al. PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). NPJ Breast Cancer. 2016;2:15023. 10.1038/npjbcancer.2015.23.28691057 10.1038/npjbcancer.2015.23
52. Cubasch H Ruff P Joffe M South African breast Cancer and HIV outcomes Study: methods and Baseline Assessment J Global Oncol 2017 3 2 114 24 10.1200/JGO.2015.002675
Cubasch H, Ruff P, Joffe M, et al. South African breast Cancer and HIV outcomes Study: methods and Baseline Assessment. J Global Oncol. 2017;3(2):114–24. 10.1200/JGO.2015.002675.10.1200/JGO.2015.002675
53. Phakathi B Nietz S Cubasch H Survival of South African women with breast cancer receiving anti-retroviral therapy for HIV Breast (Edinburgh Scotland) 2021 59 27 36 10.1016/j.breast.2021.05.014 34126376
Phakathi B, Nietz S, Cubasch H, et al. Survival of South African women with breast cancer receiving anti-retroviral therapy for HIV. Breast (Edinburgh Scotland). 2021;59:27–36. 10.1016/j.breast.2021.05.014.34126376 10.1016/j.breast.2021.05.014
